We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 in Mouse Lung Cancer.
- Authors
Di WU; Chenhui LI; Yan WANG; Zhengqiang HE; Chang'e JIN; Min GUO; Rongchang CHEN; Chengzhi ZHOU
- Abstract
Background and objective Neoantigen reactive T cell (NRT) has the ability to inhibit the growth of tumors expressing specific neoantigens. However, due to the difficult immune infiltration and the inhibition of tumor microenvironment, the therapeutic effect of NRT in solid tumors is limited. In this study, we designed NRT cells (7x19 NRT) that can express both interleukin-7 (IL-7) and chemokine C-C motif ligand 19 (CCL19) in mouse lung cancer cells, and evaluated the difference in anti-tumor effect between 7x19 NRT cells and conventional NRT cells. Methods We performed next-generation sequencing and neoantigen prediction for mouse Lewis lung carcinoma (LLC), prepared RNA vaccine, cultured NRT cells, constructed retroviral vectors encoding IL-7 and CCL19, transduced NRT cells and IL-7 and CCL19 were successfully expressed, and 7x19 NRT was successfully obtained. The anti-tumor effect was evaluated in vivo and in vitro in mice. Results The 7x19 NRT cells significantly enhanced the proliferation and invasion ability of T cells by secreting IL-7 and CCL19, achieved significant tumor inhibition in the mouse lung cancer and extended the survival period of mice. The T cell infiltration into tumor tissue and the necrosis of tumor tissue increased significantly after 7x19 NRT treatment. In addition, both 7x19 NRT treatment and conventional NRT treatment were safe. Conclusion The anti-solid tumor ability of NRT cells is significantly enhanced by the arming of IL-7 and CCL19, which is a safe and effective genetic modification of NRT.
- Subjects
CHINA; TREATMENT of lung tumors; GENE therapy; T cells; CANCER; RESEARCH funding; CELL proliferation; NECROSIS; MICE; CELL lines; LUNG tumors; ANIMAL experimentation; CYTOKINES; TUMOR antigens; INTERLEUKINS
- Publication
Chinese Journal of Lung Cancer, 2024, Vol 27, Issue 7, p504
- ISSN
1009-3419
- Publication type
Article
- DOI
10.3779/j.issn.1009-3419.2024.106.18